Home Drug IndexClinical Monograph

Botulinum Toxin B: Uses, Dosage, Side Effects & Price | DrugsAtlas

Authoritative Clinical Reference

Neuromuscular blocking agent

DRUG NAME: Botulinum Toxin B

Therapeutic Class:

Neurotoxin

Subclass:

Neuromuscular Blocking Agent

Schedule (India):

Schedule H

Routes

Intramuscular (IM)

Formulations Available in India:

Injection: 5,000 units/mL solution (0.5 mL vial — 2,500 units total)
Injection: 5,000 units/mL solution (1 mL vial — 5,000 units total)
Injection: 5,000 units/mL solution (2 mL vial — 10,000 units total)

Important Note: Botulinum Toxin B has very limited availability in India. Primarily imported on demand through specialty centres. Units are NOT interchangeable with Botulinum Toxin A products.

ADULT INDICATIONS

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

▶ Cervical Dystonia (Spasmodic Torticollis) — Adults

Parameter	Recommendation
Starting dose	2,500–5,000 units IM total, divided among affected neck muscles (sternocleidomastoid, splenius capitis, trapezius, levator scapulae)
Titration	Increase by 2,500 units per session based on clinical response; minimum 12-week interval between sessions
Usual maintenance dose	5,000–10,000 units per session every 12–16 weeks
Maximum dose	15,000 units per session (some sources cite up to 25,000 units; specialist discretion)

Clinical Notes:

Primarily reserved for patients who develop neutralising antibodies to Botulinum Toxin A
Faster onset of action (within days) but shorter duration compared to Type A
Higher incidence of autonomic side effects (dry mouth)
EMG guidance recommended for precise muscle targeting
Response typically begins within 1 week; effect duration approximately 12–16 weeks

Secondary Indications — Adults (Off-label, if any)

Indication	Dose	Duration	Notes
Sialorrhoea (Parkinson’s disease, ALS, stroke)	1,500–3,500 units total divided between bilateral parotid glands (750–1,000 units each) and submandibular glands (250–500 units each)	Effect lasts 12–16 weeks; repeat as needed	OFF-LABEL; Specialist only (Neurology/ENT); Ultrasound-guided injection preferred; Evidence: International RCTs, limited Indian experience
Focal Upper Limb Spasticity	1,500–10,000 units total distributed across affected muscles based on spasticity pattern	Repeat every 12–16 weeks	OFF-LABEL; Specialist only (PMR/Neurology); Evidence: International RCTs; Limited Indian data

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

NOT AVAILABLE in India — Botulinum Toxin B is NOT approved for paediatric use in India.

Secondary Indications — Paediatrics (Off-label, if any)

Indication	Dose	Duration	Notes
Cerebral Palsy-related Spasticity	50–100 units/kg total divided across affected muscle groups	Repeat every 12–16 weeks	OFF-LABEL; Specialist only (Paediatric Neurology/PMR); Very limited experience; Extrapolated from international data

Minimum Age: Not recommended below 16 years except under specialist supervision in tertiary centres with extensive experience.

Maximum Paediatric Dose: Lower of 10,000 units total OR 200 units/kg per session.

Safety Monitoring:

Close observation for 48–72 hours post-injection
Monitor for dysphagia, respiratory difficulty, generalised weakness
Assess swallowing function before discharge
Nutritional and growth monitoring with repeated use

Note: Botulinum Toxin A is preferred for paediatric indications due to greater experience and safety data.

RENAL ADJUSTMENT

No dosage adjustment required
Botulinum toxin acts locally at neuromuscular junction with negligible systemic absorption
Use with caution in patients with significant renal dysfunction due to limited excretion data

HEPATIC ADJUSTMENT

Severity	Recommendation
Mild impairment	No dose adjustment required
Moderate impairment	No specific adjustment; use with caution
Severe impairment	Use with caution; no hepatic metabolism but altered protein reserves may affect clinical response; specialist decision

CONTRAINDICATIONS

Known hypersensitivity to Botulinum Toxin B or formulation excipients (human albumin, sodium succinate, sodium chloride)
Infection at proposed injection site
Generalised disorders of neuromuscular transmission (myasthenia gravis, Lambert-Eaton myasthenic syndrome)
Concurrent use of aminoglycosides or other agents interfering with neuromuscular transmission (delay botulinum injection)

CAUTIONS

Pre-existing dysphagia or respiratory compromise — increased aspiration risk
History of aspiration pneumonia
Cardiovascular disease — autonomic effects (dry mouth, constipation) more pronounced with Type B
Elderly patients — increased sensitivity to systemic effects
Patients with pre-existing neuromuscular disorders (motor neurone disease, peripheral neuropathy)
Previous exposure to any botulinum toxin — assess for antibody formation
Concomitant use with anticoagulants — increased bruising risk at injection sites
Repeated high-dose use — risk of neutralising antibody development

PREGNANCY

Parameter	Recommendation
Risk Category	Category C — Avoid unless clearly necessary
Safety Data	No adequate human studies; animal studies show fetal toxicity at high doses
Preferred Alternatives	Conservative management; Botulinum Toxin A has more safety data if botulinum therapy essential
When May Be Used	Only for severe, debilitating dystonia unresponsive to other treatments; specialist decision only
Monitoring	Fetal movement monitoring; ultrasound assessment if administered during pregnancy

LACTATION

Parameter	Recommendation
Compatibility	Not recommended during breastfeeding
Expected Levels in Milk	Likely negligible due to large molecular size (150 kDa) and local action
Preferred Alternatives	Botulinum Toxin A if treatment essential (more characterised); defer treatment if possible
Infant Monitoring	If unavoidable: monitor feeding pattern, muscle tone, weight gain

ELDERLY

Parameter	Recommendation
Starting Dose	Use lower end of dosing range (2,500 units for cervical dystonia)
Titration	Slower titration; minimum 12-week interval; assess response before dose escalation
Extra Risks	Increased sensitivity to autonomic effects (dry mouth, constipation, urinary retention); dysphagia risk; generalised weakness; falls risk
Monitoring	Close observation for systemic effects; swallowing assessment mandatory for cervical injections

MAJOR DRUG INTERACTIONS

Interacting Drug	Effect	Management
Aminoglycosides (gentamicin, amikacin, streptomycin)	Potentiate neuromuscular blockade; risk of respiratory compromise	Avoid concurrent use; delay botulinum if aminoglycoside therapy ongoing
Non-depolarising muscle relaxants (vecuronium, atracurium, rocuronium)	Additive neuromuscular blockade	Avoid elective procedures requiring NMBAs within 2–4 weeks of botulinum injection
Other botulinum toxin products (Type A or B)	Cumulative toxicity; unpredictable response	Do not administer different botulinum products concurrently or within close interval
Spectinomycin, polymyxins, lincosamides (clindamycin)	Potentiate neuromuscular blockade	Avoid combination; if essential, monitor closely for weakness
Magnesium sulphate	Potentiates neuromuscular effects	Caution in eclampsia management if botulinum recently administered

MODERATE DRUG INTERACTIONS

Interacting Drug	Effect	Management
Anticholinergics (oxybutynin, trihexyphenidyl, glycopyrrolate)	Additive anticholinergic effects (dry mouth, constipation, urinary retention); more pronounced with Type B	Monitor for anticholinergic toxicity; consider dose reduction of anticholinergic
Muscle relaxants (baclofen, tizanidine)	Additive muscle weakness	Use with caution; monitor for excessive weakness
Anticoagulants/Antiplatelets (warfarin, aspirin, clopidogrel)	Increased bruising at injection sites	Consider temporary hold if feasible; apply pressure post-injection
Quinidine, quinine	May potentiate neuromuscular effects	Monitor for excessive weakness
CNS depressants (benzodiazepines, opioids)	Additive sedation with systemic diffusion (rare)	Monitor in elderly; caution with high doses

COMMON ADVERSE EFFECTS

Dry mouth (very common with Type B; up to 30–40%)
Dysphagia (especially with cervical injections; 10–25%)
Injection site pain, erythema, bruising
Neck pain or stiffness
Headache
Nausea
Flu-like symptoms
Taste disturbance
Blurred vision (with periocular injections)

SERIOUS ADVERSE EFFECTS

Generalised muscle weakness — rare; potentially life-threatening; requires immediate medical attention
Respiratory compromise/failure — especially in patients with pre-existing respiratory disease or high doses
Aspiration pneumonia — secondary to dysphagia; higher risk in elderly and cervical dystonia patients
Systemic botulism-like syndrome — distant spread of toxin effect causing generalised weakness, respiratory difficulty
Anaphylaxis/hypersensitivity reactions — rare; discontinue and treat as emergency
Autonomic instability — rare; may require urgent management

Action Required: Discontinue immediately if generalised weakness, respiratory difficulty, or anaphylaxis occurs. Provide supportive care; hospitalisation may be required.

MONITORING REQUIREMENTS

Phase	Parameters
Baseline	Complete neuromuscular examination; document severity (TWSTRS for cervical dystonia); assess swallowing function (cervical indications); prior botulinum exposure history
Post-injection (24–72 hours)	Observe for dysphagia, respiratory difficulty, generalised weakness; counsel patient/caregiver on warning signs
Short-term (2–4 weeks)	Assess clinical response; document improvement in dystonia severity
Long-term	Re-evaluate efficacy every 3–4 months; monitor for waning response suggesting neutralising antibody formation; reassess indication at each cycle

BRANDS AVAILABLE IN INDIA

Myobloc® (Solstice Neurosciences/US Worldmeds) — imported on demand; very limited availability
NeuroBloc® (Eisai/Sloan Pharma) — European equivalent; rarely available in India

Note: Botulinum Toxin B products have very limited availability in India. Most specialists use Botulinum Toxin A products (Botox®, Dysport®, Xeomin®) as first-line. Type B is typically sourced through special import for refractory cases.

PRICE RANGE (INR)

Formulation	Approximate Price	Notes
2,500 units vial	₹18,000–25,000	Imported; price variable
5,000 units vial	₹30,000–45,000	Limited supply
10,000 units vial	₹55,000–75,000	Specialist procurement

Not included in NLEM; not under NPPA price control
Available primarily through tertiary neurology centres and specialty import
Significant price variability due to import costs

CLINICAL PEARLS

Primary role in India: Reserved for patients with documented resistance (neutralising antibodies) to Botulinum Toxin A; not first-line therapy
Unit non-interchangeability: Type B units are NOT equivalent to Type A units — do not attempt dose conversion; start fresh titration when switching
Autonomic profile: Greater anticholinergic effects (dry mouth occurs in up to 40%) compared to Type A — warn patients and consider in elderly/those on anticholinergics
Onset and duration: Faster onset (days vs weeks) but potentially shorter duration of action compared to Type A
Antibody development: Patients who develop antibodies to Type A may also eventually develop antibodies to Type B with repeated use
Storage: Store refrigerated at 2–8°C; do not freeze; once opened, use within 4 hours

VERSION

RxIndia v0.2 — 03 Feb 2026

REFERENCES

CDSCO import regulations for biologicals
Indian Pharmacopoeia (botulinum toxins — general)
AIIMS Neurology Department protocols
Indian Movement Disorder Society recommendations
Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
Harrison’s Principles of Internal Medicine
API Textbook of Medicine
International RCTs — used for off-label indications only (sialorrhoea, spasticity)
US FDA prescribing information for Myobloc (reference)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...